Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Research & Development (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Research & Development for 11 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 29.92% to $14.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $58.0 million, a 28.66% increase, with the full-year FY2025 number at $58.0 million, up 28.66% from a year prior.
  • Research & Development was $14.7 million for Q4 2025 at Cartesian Therapeutics, up from $13.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $21.9 million in Q4 2023 to a low of $9.7 million in Q1 2024.
  • A 5-year average of $15.8 million and a median of $14.8 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 48.26% in 2024, then surged 50.69% in 2025.
  • Cartesian Therapeutics' Research & Development stood at $20.3 million in 2021, then decreased by 6.65% to $19.0 million in 2022, then rose by 15.21% to $21.9 million in 2023, then crashed by 48.26% to $11.3 million in 2024, then increased by 29.92% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Research & Development are $14.7 million (Q4 2025), $13.8 million (Q3 2025), and $14.9 million (Q2 2025).